BLUE - bluebird bio, Inc.
After hours:
| Previous close | 3.4800 |
| Open | 3.4600 |
| Bid | 3.5600 x 3200 |
| Ask | 3.5700 x 3000 |
| Day's range | 3.4400 - 3.6100 |
| 52-week range | 2.7800 - 8.5800 |
| Volume | |
| Avg. volume | 4,784,941 |
| Market cap | 378.827M |
| Beta (5Y monthly) | 0.93 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.4700 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 6.90 |
Simply Wall St.Will bluebird bio (NASDAQ:BLUE) Spend Its Cash Wisely?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...
Business Wirebluebird bio Reports First Quarter 2023 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass., May 09, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the first quarter ended March 31, 2023, including recent commercial and operational progress, and regulatory updates.
Business Wirebluebird bio Announces First Quarter 2023 Earnings Date and Upcoming Investor Events
SOMERVILLE, Mass., April 27, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that the Company’s first quarter financial results, including commercial, regulatory and operational updates, will be released pre-market on Tuesday, May 9.
Business Wirebluebird bio Submits Biologics License Application (BLA) to FDA for lovotibeglogene autotemcel (lovo-cel) for Patients with Sickle Cell Disease (SCD) 12 years and Older with a History of Vaso-Occlusive Events
SOMERVILLE, Mass., April 24, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced the submission of its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lovotibeglogene autotemcel (lovo-cel) gene therapy in patients with sickle cell disease (SCD) ages 12 and older who have a history of vaso-occlusive events (VOEs). The BLA includes a request for Priority Review, which, if granted, would shorten the FDA’s review of the application to six months from the ti
Motley FoolShould Investors Buy the Dip With Bluebird Bio Stock?
With the stock down 52% in the last three months, Bluebird Bio (NASDAQ: BLUE) shareholders are bound to be feeling pretty antsy. Between the company's weak cash position, missed deadline for a drug candidate submission to regulators, and 30% cut in its workforce a year ago, there hasn't been much to celebrate lately. First, while it did miss its goal of submitting its approval packet for a therapy called lovo-cel to the Food and Drug Administration (FDA) in the first quarter, it says that once the FDA gets back to it in a few weeks, it'll do so.
Motley FoolWhat's the Better Dip to Buy: CRISPR Therapeutics vs. Bluebird Bio
The last 12 months haven't been kind to the likes of gene editing stocks like CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE). Whereas CRISPR's shares fell by 31%, Bluebird's are down by 33%. CRISPR Therapeutics is on track to have a transformative 2023, but its biggest risk is that regulators will stymie its efforts to commercialize its gene therapy candidate exa-cel, which aims to treat beta thalassemia and sickle cell disease.
Motley FoolBetter Gene-Editing Stock: Editas Medicine vs. Bluebird Bio
Editas Medicine (NASDAQ: EDIT) and Bluebird Bio (NASDAQ: BLUE) are both beaten-down gene-editing stocks. Editas' shares are down by 65% in the last 12 months, whereas Bluebird's have fallen by 40%. The question of which company is the better gene-editing stock for long-term investment is largely a question of which of these two biotechs has a higher chance of surviving over the next three years.
Motley Fool1 Small-Cap Stock That Could Soar in 2023
Last year was an important one for Bluebird Bio (NASDAQ: BLUE) as the biotech company earned two key regulatory approvals in the U.S. Despite these wins, the market has hardly rewarded the gene-editing specialist; its shares are down 39% in the past year, and Bluebird's market capitalization is currently just $323 million. The company's newly approved therapies are Zynteglo, which targets transfusion-dependent beta-thalassemia (TDT, a rare blood disorder), and Skysona, a medicine for cerebral adrenoleukodystrophy (CALD, a progressive, pediatric, and fatal neurodegenerative disease). The issue here is whether third-party payers will agree to cover these medicines.
Motley FoolWhy Bluebird Bio Stock Is Sinking This Week
Shares of the gene therapy pioneer Bluebird Bio (NASDAQ: BLUE) have been under heavy pressure this week. Investors hit the exits after the company revealed that it may miss the first-quarter submission goal for lovo-cel's Biologics License Application (BLA) to the Food and Drug Administration (FDA). Lovo-cel is an experimental gene therapy in development for the rare blood disorder sickle cell disease.
ZacksBluebird Bio (BLUE) Reports Q4 Loss, Misses Revenue Estimates
Bluebird (BLUE) delivered earnings and revenue surprises of -26.67% and 99.94%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Business Wirebluebird bio Reports Fourth Quarter and Full Year 2022 Financial Results and Highlights Operational Progress
SOMERVILLE, Mass., March 29, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today reported financial results and business highlights for the fourth quarter and full year ended December 31, 2022 including recent commercial and operational progress, and regulatory updates.
- Zacks
Bluebird Bio (BLUE) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
Bluebird (BLUE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Motley Fool1 Beaten-Down Stock That Has a Lot to Prove in 2023
The past several years have been brutal for biotech company Bluebird bio (NASDAQ: BLUE). Shares of the gene-editing specialist are down by 85% since early 2020 as it has had to deal with clinical and regulatory setbacks, not to mention the marketwide headwinds that have impacted all equities.
- Simply Wall St.
bluebird bio, Inc. (NASDAQ:BLUE) is favoured by institutional owners who hold 58% of the company
Every investor in bluebird bio, Inc. ( NASDAQ:BLUE ) should be aware of the most powerful shareholder groups. And the...
ZacksZacks.com featured highlights include bluebird bio, Pros Holdings and Norwegian Cruise Line
bluebird bio, Pros Holdings and Norwegian Cruise Line are part of the Zacks Screen of the Week article.
Motley FoolBetter Biotech Buy: Bluebird Bio or CRISPR Therapeutics?
Last year paved the way for a potential breakthrough this year for both gene-editing biotech companies.
Business Wirebluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common Stock
SOMERVILLE, Mass., January 19, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced the pricing of its underwritten public offering of 20,000,000 shares of its common stock at a public offering price of $6.00 per share, before deducting underwriting discounts and commissions. bluebird also granted the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock at the public offering price per share, less underwriting discounts and commissions
Motley FoolModerna Gets Good News, but Another Biotech Stock Is Falling Again
Just as the Nasdaq Composite (NASDAQINDEX: ^IXIC) led markets lower in 2022, the index is working hard to lead a rebound early in 2023. After being the only one of the three major U.S. stock market indexes to finish higher on Tuesday, the Nasdaq once again looked good early Wednesday morning, with futures on the index rising nearly half a percent. One winner leading the Nasdaq higher Wednesday morning was vaccine stock Moderna (NASDAQ: MRNA), which announced positive news that showed investors the company is more than just a one-trick pony.
Business Wirebluebird bio, Inc. Announces Proposed Public Offering of Common Stock
SOMERVILLE, Mass., January 18, 2023--bluebird bio, Inc. (Nasdaq: BLUE) ("bluebird") today announced that it has commenced an underwritten public offering of 20,000,000 shares of its common stock. bluebird also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock to be sold in the offering. The offering, actual size and terms are subject to market conditions, and there can be no assurance as to whether or when the offering may be c
Business Wirebluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass., January 09, 2023--bluebird bio, Inc. (Nasdaq: BLUE) (the Company) today announced updates to be presented at the 41st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT.
Motley Fool2 Stocks That Could Double Your Money in 2023
After all, many currently well-established companies were once small- or mid-cap stocks. Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled. The company could carry this momentum into this year.
Business Wirebluebird bio Sells Second Priority Review Voucher for $95 Million
SOMERVILLE, Mass., January 06, 2023--bluebird bio, Inc. (NASDAQ: BLUE) ("bluebird bio" or the "Company") today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher (PRV) for $95 million.
Business Wirebluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conference
SOMERVILLE, Mass., January 05, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT.
Business Wirebluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer
SOMERVILLE, Mass., January 03, 2023--bluebird bio, Inc. (Nasdaq: BLUE) today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. Vittiglio brings more than 20 years of experience in the biopharmaceutical industry, with expertise in licensing, collaborations and mergers and acquisitions, financial transactions, FDA regulations, compliance, manufacturing, and quality operations for organizations at all stages of development.
Motley FoolAfter Doubling in the Past 6 Months, Is This Stock a Buy?
It's been a wild 12 months for biotech company Bluebird Bio (NASDAQ: BLUE). Bluebird earned approval from the U.S. Food and Drug Administration (FDA) for Zynteglo and Skysona in August and September, respectively.